Introduction: Who Should Undergo Diagnostics and When

Patients with precursor B-lymphoblastic lymphoma who experience refractory disease (meaning the cancer doesn’t respond to initial treatment) or relapsed disease (when the cancer returns after a period of remission) need careful and thorough diagnostic evaluation. Refractory disease means that previous treatments did not kill enough cancer cells to achieve a complete remission, while relapsed disease indicates that the lymphoma has come back after responding to earlier therapy.^[11]

Anyone who shows signs that their lymphoma may not be responding to treatment should be evaluated as soon as possible. This includes patients who continue to have symptoms after several cycles of chemotherapy, or those whose blood tests or other monitoring suggest the disease is still active. Similarly, individuals who were previously in remission but begin experiencing new or returning symptoms need prompt diagnostic assessment. The prognosis for patients with refractory or relapsed precursor B-cell acute lymphoblastic leukemia remains poor, making early and accurate diagnosis essential for planning the next steps in care.^[1][4]

Children and young adults with this condition face particularly serious challenges. While current treatments can achieve five-year remission in over 90% of newly diagnosed children with B-cell precursor acute lymphoblastic leukemia, the outlook becomes much more difficult for those whose disease doesn’t respond or returns.^[4] The difference between lymphoblastic lymphoma and leukemia is based on how much the bone marrow is involved—if less than 20% of the bone marrow contains cancer cells, it’s called lymphoma; if 20% or more, it’s called leukemia. However, both conditions are treated very similarly and share many characteristics.^[2]

Diagnostic Methods

Bone Marrow Examination

One of the most important diagnostic procedures for identifying refractory or relapsed precursor B-lymphoblastic lymphoma is bone marrow examination. This test involves taking a sample of bone marrow, usually from the hip bone, to look for cancer cells under a microscope. The key distinction between lymphoma and leukemia depends on what percentage of the bone marrow is filled with abnormal cells called lymphoblasts, which are immature cancer cells. If the bone marrow contains less than 20% lymphoblasts, the disease is classified as lymphoblastic lymphoma; if it contains 20% or more, it is classified as acute lymphoblastic leukemia.^[2]

During this examination, doctors also perform special tests on the cells to identify their characteristics. One crucial test determines whether the cancer cells express certain proteins on their surface, particularly CD19, which is a marker found on B-cells. This information becomes especially important when considering newer treatment options, since some modern therapies specifically target cells that carry CD19.^[4] Knowing whether the lymphoma cells are CD19-positive helps doctors select the most appropriate treatment approach.

Imaging Studies

Advanced imaging techniques play a vital role in understanding how much disease is present and where it is located in the body. PET/CT imaging (positron emission tomography combined with computed tomography) uses a radioactive tracer called 18F-fluorodeoxyglucose to detect active cancer cells throughout the body. Cancer cells typically consume more sugar than normal cells, so they show up as bright spots on the scan. This imaging method is particularly useful for monitoring how well treatment is working and detecting whether the disease has returned.^[5]

In one documented case, a 44-year-old patient with precursor B-cell lymphoblastic lymphoma involving the central nervous system showed intense uptake of the radioactive tracer on initial PET/CT imaging. After treatment, follow-up scans showed complete disappearance of the abnormal uptake, confirming that the patient had achieved remission.^[5] This example illustrates how PET/CT can be used not just for initial diagnosis, but also for tracking response to treatment over time.

Other imaging studies such as CT scans, MRI (magnetic resonance imaging), and ultrasound may also be used depending on where the lymphoma is suspected to be located. Brain MRI might be ordered if there are concerns about central nervous system involvement, while chest X-rays or CT scans can identify masses in the chest area, which are common in lymphoblastic lymphoma.

Blood Tests and Laboratory Analysis

Blood tests provide important information about the disease and the patient’s overall health status. A complete blood count measures the levels of different blood cells, which can be abnormal when lymphoma is present or has spread to the bone marrow. Additional blood tests check kidney and liver function, electrolyte levels, and other markers that help doctors understand how the disease is affecting the body.

Specialized tests can detect minimal residual disease (MRD), which refers to small numbers of cancer cells that remain in the body after treatment but are too few to detect with standard tests. High-sensitivity testing methods can find these remaining cells, and the presence of MRD is an important predictor of whether the disease is likely to come back. Patients with detectable MRD after treatment generally have a higher risk of relapse than those who achieve MRD-negative status.^[7][9]

Tissue Biopsy

When lymphoma is suspected to be growing in lymph nodes or other tissues outside the bone marrow, doctors may perform a biopsy. This involves removing a small piece of tissue for examination under a microscope. The biopsy sample undergoes several types of analysis, including looking at the cell structure and shape, testing for specific protein markers on the cell surface (immunophenotyping), and checking for genetic abnormalities.

Genetic testing of the biopsy sample can reveal important information such as whether the cancer cells carry the Philadelphia chromosome, a specific genetic abnormality that results from a fusion between two genes. When present, this finding may influence treatment decisions, as certain medications specifically target this genetic change.^[5]

Central Nervous System Assessment

Because precursor B-lymphoblastic lymphoma can spread to the brain and spinal cord, evaluation of the central nervous system (CNS) is an important part of diagnosis. Doctors perform a procedure called lumbar puncture or spinal tap, where a needle is inserted into the lower back to collect a sample of cerebrospinal fluid, the liquid that surrounds the brain and spinal cord. This fluid is examined for the presence of cancer cells.

Finding lymphoma cells in the cerebrospinal fluid indicates CNS involvement, which requires specific treatment approaches to address the disease in this location. In some cases, imaging of the brain and spine with MRI provides additional information about whether masses or other abnormalities are present in the central nervous system.^[5]

Diagnostics for Clinical Trial Qualification

When standard treatments have not worked or the disease has returned, many patients with refractory or relapsed precursor B-lymphoblastic lymphoma are considered for clinical trials testing new therapies. These trials have specific requirements that must be met before a patient can enroll, and certain diagnostic tests are performed to determine eligibility.

Disease Status Confirmation

Clinical trials typically require documented evidence that the lymphoma is truly refractory or relapsed. This means having bone marrow examination results showing that cancer cells are still present despite previous treatment, or evidence from imaging or other tests that the disease has returned after a period of remission. Some trials may accept patients with either morphological remission (meaning no visible cancer cells under the microscope) or those with active disease, depending on the study design.^[4]

The timing and extent of relapse may also matter. A relapse that occurs soon after treatment often indicates more aggressive disease compared to one that happens years later. Some clinical trials specifically target patients who have relapsed after stem cell transplantation, which represents a particularly difficult situation since this treatment is often considered the most intensive option available.^[4]

CD19 Expression Testing

Many newer treatments for B-cell lymphomas, including some being tested in clinical trials, specifically target the CD19 protein found on the surface of B-cells. Therefore, confirming that the cancer cells are CD19-positive is often a requirement for participation. This is determined through immunophenotyping, a laboratory technique that identifies specific proteins on cell surfaces.

For example, clinical trials testing CAR-T cell therapy (chimeric antigen receptor T-cell therapy) for relapsed precursor B-cell acute lymphoblastic leukemia typically require that patients have CD19-positive disease. In one single-center analysis, six pediatric patients with relapsed CD19-positive disease were qualified for CAR-T therapy, and all achieved remission.^[4] Before receiving this treatment, patients must undergo testing to confirm CD19 expression on their cancer cells.

Minimal Residual Disease Assessment

Some clinical trials specifically enroll patients based on their minimal residual disease status. Highly sensitive laboratory techniques can detect as few as one cancer cell among thousands or even millions of normal cells. These methods include flow cytometry, which uses lasers to identify cells based on their surface proteins, and molecular tests that detect genetic material specific to the cancer cells.

Patients who have MRD-positive disease (meaning small numbers of cancer cells remain detectable) may be candidates for trials testing whether additional treatment can eliminate these residual cells and prevent relapse. Conversely, some studies enroll patients who are already in remission to test whether new therapies can keep the disease from coming back.^[9]

Performance Status and Organ Function

Clinical trials require evidence that patients are healthy enough to tolerate the experimental treatment being tested. This involves measuring overall functional status, typically using standardized scoring systems that assess how well a person can perform daily activities. Blood tests evaluate kidney function, liver function, and bone marrow reserves to ensure these organs are working adequately.

For trials testing immunotherapy approaches such as blinatumomab (a bispecific antibody that engages both CD19 on cancer cells and CD3 on immune cells), specific safety assessments may be required. These might include neurological examination to establish a baseline, since some immunotherapies can cause temporary neurological side effects.^[1]

Prior Treatment History

Documentation of all previous treatments is essential for clinical trial qualification. Trial coordinators need to know exactly what chemotherapy drugs were used, when stem cell transplantation was performed if applicable, and what response was achieved with each treatment line. Some trials specifically enroll patients who have received a certain number of prior therapies, while others may exclude patients who have already been exposed to similar treatments.

For instance, clinical trials of new antibody-based treatments may exclude patients who have already received other antibody therapies, to ensure that any response observed is due to the study drug rather than lingering effects of previous similar treatments. Conversely, some trials specifically seek patients who have failed multiple standard approaches, as these individuals have the greatest unmet medical need.^[6]